AI assistant
Senzime — Share Issue/Capital Change 2023
Nov 30, 2023
3198_rns_2023-11-30_74b2dafa-4975-40f7-ac80-dcefa8c7f64d.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
PRESS RELEASE 30 November 2023 15:00:00 CET
New number of shares and votes in Senzime AB (publ)
The number of shares and votes in Senzime AB (publ) ("Senzime") has during the month of November increased due to the directed share issue resolved by the board of directors on 25 September 2023 and approved by an extraordinary general meeting of shareholders on 19 October 2023 and the directed share issue resolved by the board on 7 November 2023. In the directed share issues, 19,582,909 new shares were issued.
As of 30 November 2023, the total number of shares in Senzime amounts to 119,705,523 (previously 100,122,614 shares), with one vote each. The share capital amounts to SEK 14,963,190.375 (previously SEK 12,515,326.75).
As of 30 November 2023, Senzime holds no treasury shares.
For further information, please contact:
Philip Siberg, CEO of Senzime AB Phone: +46 (0) 707 90 67 34, e-mail: [email protected]
Slavoljub Grujicic, CFO Phone: +46 (0) 76 306 60 11, e-mail: [email protected]
About Senzime
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDAcleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com.
This information is information that Senzime is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-11-30 15:00 CET.